Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models

Darolutamide is a novel androgen receptor (AR) antagonist with a distinct chemical structure compared to other AR antagonists and currently in clinical Phase 3 trials for prostate cancer. Using cell‐based transactivation assays, we demonstrate that darolutamide, its diastereomers and its main metabo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugawara, Tatsuo, Baumgart, Simon J., Nevedomskaya, Ekaterina, Reichert, Kristin, Steuber, Holger, Lejeune, Pascale, Mumberg, Dominik, Haendler, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Molecular Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766977/
https://www.ncbi.nlm.nih.gov/pubmed/30828788
http://dx.doi.org/10.1002/ijc.32242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766977/
https://www.ncbi.nlm.nih.gov/pubmed/30828788
http://dx.doi.org/10.1002/ijc.32242

Ejemplares similares